Terajima Masanori, Cruz John, Leporati Anita M, Orphin Laura, Babon Jenny Aurielle B, Co Mary Dawn T, Pazoles Pamela, Jameson Julie, Ennis Francis A
Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA.
J Virol. 2008 Sep;82(18):9283-7. doi: 10.1128/JVI.01047-08. Epub 2008 Jul 9.
Among 17 HLA-A2-positive healthy adults, CD8+ T-cell responses against an HLA-A2-restricted matrix protein 1 (M1) epitope increased after immunization with trivalent inactivated influenza vaccine (TIV) in two individuals. The presence of M1 in TIV was confirmed by Western blotting. T-cell cytotoxicity assays showed that TIV is processed and the epitope is presented by antigen-presenting cells to an M1 epitope-specific CD8+ T-cell line for specific lysis. These data show that TIV, which is formulated to contain surface glycoproteins to induce serotype-specific antibody responses, also contains M1, capable of inducing subtype cross-reactive CD8+ T-cell responses in some vaccinees.
在17名HLA - A2阳性健康成年人中,有两人在接种三价灭活流感疫苗(TIV)后,针对HLA - A2限制性基质蛋白1(M1)表位的CD8 + T细胞反应增强。通过蛋白质免疫印迹法证实了TIV中存在M1。T细胞细胞毒性试验表明,TIV被加工处理,且该表位由抗原呈递细胞呈递给M1表位特异性CD8 + T细胞系进行特异性裂解。这些数据表明,TIV的配方旨在包含表面糖蛋白以诱导血清型特异性抗体反应,同时也含有M1,能够在一些接种者中诱导亚型交叉反应性CD8 + T细胞反应。